BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 30736768)

  • 21. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.
    Rexer BN; Ghosh R; Narasanna A; Estrada MV; Chakrabarty A; Song Y; Engelman JA; Arteaga CL
    Clin Cancer Res; 2013 Oct; 19(19):5390-401. PubMed ID: 23948973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting of the HER2/HER3 signaling axis overcomes ligand-mediated resistance to trastuzumab in HER2-positive breast cancer.
    Watanabe S; Yonesaka K; Tanizaki J; Nonagase Y; Takegawa N; Haratani K; Kawakami H; Hayashi H; Takeda M; Tsurutani J; Nakagawa K
    Cancer Med; 2019 Mar; 8(3):1258-1268. PubMed ID: 30701699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidermal growth factor receptor ligands as new extracellular targets for the metastasis-promoting S100A4 protein.
    Klingelhöfer J; Møller HD; Sumer EU; Berg CH; Poulsen M; Kiryushko D; Soroka V; Ambartsumian N; Grigorian M; Lukanidin EM
    FEBS J; 2009 Oct; 276(20):5936-48. PubMed ID: 19740107
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new model system identifies epidermal growth factor receptor-human epidermal growth factor receptor 2 (HER2) and HER2-human epidermal growth factor receptor 3 heterodimers as potent inducers of oesophageal epithelial cell invasion.
    Fichter CD; Przypadlo CM; Buck A; Herbener N; Riedel B; Schäfer L; Nakagawa H; Walch A; Reinheckel T; Werner M; Lassmann S
    J Pathol; 2017 Dec; 243(4):481-495. PubMed ID: 28940194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
    Shou J; Massarweh S; Osborne CK; Wakeling AE; Ali S; Weiss H; Schiff R
    J Natl Cancer Inst; 2004 Jun; 96(12):926-35. PubMed ID: 15199112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
    Huang Y; Li X; Jiang J; Frank SJ
    Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
    [TBL] [Abstract][Full Text] [Related]  

  • 27. NRF1 motif sequence-enriched genes involved in ER/PR -ve HER2 +ve breast cancer signaling pathways.
    Ramos J; Das J; Felty Q; Yoo C; Poppiti R; Murrell D; Foster PJ; Roy D
    Breast Cancer Res Treat; 2018 Nov; 172(2):469-485. PubMed ID: 30128822
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Crude phenolic extracts from extra virgin olive oil circumvent de novo breast cancer resistance to HER1/HER2-targeting drugs by inducing GADD45-sensed cellular stress, G2/M arrest and hyperacetylation of Histone H3.
    Oliveras-Ferraros C; Fernández-Arroyo S; Vazquez-Martin A; Lozano-Sánchez J; Cufí S; Joven J; Micol V; Fernández-Gutiérrez A; Segura-Carretero A; Menendez JA
    Int J Oncol; 2011 Jun; 38(6):1533-47. PubMed ID: 21455577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways.
    Kovacevic Z; Menezes SV; Sahni S; Kalinowski DS; Bae DH; Lane DJ; Richardson DR
    J Biol Chem; 2016 Jan; 291(3):1029-52. PubMed ID: 26534963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reciprocal regulation of annexin A2 and EGFR with Her-2 in Her-2 negative and herceptin-resistant breast cancer.
    Shetty PK; Thamake SI; Biswas S; Johansson SL; Vishwanatha JK
    PLoS One; 2012; 7(9):e44299. PubMed ID: 22957061
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer.
    Kim JW; Kim DK; Min A; Lee KH; Nam HJ; Kim JH; Kim JS; Kim TY; Im SA; Park IA
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):157-65. PubMed ID: 26195282
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
    Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
    J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer.
    Merry CR; McMahon S; Forrest ME; Bartels CF; Saiakhova A; Bartel CA; Scacheri PC; Thompson CL; Jackson MW; Harris LN; Khalil AM
    Oncotarget; 2016 Aug; 7(33):53230-53244. PubMed ID: 27449296
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of the EGFR/HER2 kinase inhibitor GW572016 on EGFR- and HER2-overexpressing breast cancer cell line proliferation, radiosensitization, and resistance.
    Zhou H; Kim YS; Peletier A; McCall W; Earp HS; Sartor CI
    Int J Radiat Oncol Biol Phys; 2004 Feb; 58(2):344-52. PubMed ID: 14751502
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Atomic force microscopy study of the effect of HER 2 antibody on EGF mediated ErbB ligand-receptor interaction.
    Zhang X; Shi X; Xu L; Yuan J; Fang X
    Nanomedicine; 2013 Jul; 9(5):627-35. PubMed ID: 23219876
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of Wnt3 activates Wnt/β-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells.
    Wu Y; Ginther C; Kim J; Mosher N; Chung S; Slamon D; Vadgama JV
    Mol Cancer Res; 2012 Dec; 10(12):1597-606. PubMed ID: 23071104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The phospholipase D inhibitor FIPI potently blocks EGF-induced calcium signaling in human breast cancer cells.
    Stricker HM; Rommerswinkel N; Keil S; Gnoth SA; Niggemann B; Dittmar T
    Cell Commun Signal; 2021 Apr; 19(1):43. PubMed ID: 33832505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
    Formisano L; Nappi L; Rosa R; Marciano R; D'Amato C; D'Amato V; Damiano V; Raimondo L; Iommelli F; Scorziello A; Troncone G; Veneziani B; Parsons SJ; De Placido S; Bianco R
    Breast Cancer Res; 2014 May; 16(3):R45. PubMed ID: 24887236
    [TBL] [Abstract][Full Text] [Related]  

  • 40. β-Heregulin impairs EGF induced PLC-γ1 signalling in human breast cancer cells.
    Rommerswinkel N; Keil S; Adawy A; Hengstler JG; Niggemann B; Zänker KS; Dittmar T
    Cell Signal; 2018 Dec; 52():23-34. PubMed ID: 30165102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.